Kids Menu

DGCI gives nod for phase 2/3 trials of Biological E jab on kids

For Quick Alerts

Subscribe Now
 

For Quick Alerts

ALLOW NOTIFICATIONS
 

|

Google Oneindia News

New Delhi, Sep 01: The Drugs Controller General of India (DCGI) on Wednesday granted permission to Hyderabad-based Biological E Limited to conduct phase 2/3 clinical trials of its ‘Made in India’ COVID-19 vaccine on children aged between 5 and 18 years with certain conditions, sources said.

Representational Image
Representational Image

The phase 2 and 3 clinical trials have be conducted as per approved protocol titled ‘A Prospective, Randomised, Double-blind, Placebo controlled, Phase-2/3 Study to Evaluate Safety, Reactogenicity, Tolerability and Immunogenicity of Corbevax Vaccine in Children and Adolescents’, a source said. The trial will be conducted across 10 sites in the country.

The DCGI’s permission was given based on the recommendations by the Subject Expert Committee (SEC) on COVID-19. So far, indigenously developed Zydus Cadila’s needle-free COVID-19 vaccine ZyCoV-D has received Emergency Use Authorisation from the drug regulator, making it the first vaccine to be administered in the age group of 12-18 years in the country.

Meanwhile, the data of phase 2/3 clinical trials of Bharat Biotech’s Covaxin in the age group 2 to 18 years is underway. India’s drug regulator in July granted permission to Serum Institute of India (SII) for conducting phase 2/3 trials of Covovax on children aged 2 to 17 years with certain conditions.

Biological E’s anti-coronavirus shot, Corbevax, which is a RBD protein sub-unit vaccine is currently undergoing phase 2/3 clinical trials on adults, sources had said earlier. Biological E will supply 30 crore doses of Corbevax to the central government by December, as announced by the Union Health Ministry in June.

The ministry finalised arrangements with the Hyderabad-based vaccine manufacturer to reserve 30 crore vaccine doses, an official statement had said. The Biological E COVID-19 vaccine candidate has been supported by Government of India from preclinical stage to phase 3 studies.

The Department of Biotechnology has not only provided financial assistance in terms of grant-in-aid of over Rs 100 crore but has also partnered with Biological E to conduct all animal challenge and assay studies through its Research Institute Translational Health Science Technology Institute (THSTI), Faridabad, a Health Ministry statement had stated.

Read More

Related posts
Kids Menu

FDA-approved Covid vaccine for kids ages 5 to 11 'very feasible' by Halloween, says former FDA commissioner

Kids Menu

Pfizer’s data on COVID vaccines for young kids has some important footnotes

Kids Menu

Pfizer says its Covid vaccine is safe and generates robust immune response in kids ages 5 to 11

Kids Menu

COVID-19 vaccine safe and protective in kids aged 5-11: Pfizer/BioNTech

LET'S BE FRIENDS

Get exclusive recipes,
tips and more!

Leave a Reply

Your email address will not be published. Required fields are marked *